

# Hematologic Malignancies-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/H0F20917686MEN.html>

Date: May 2018

Pages: 151

Price: US\$ 2,480.00 (Single User License)

ID: H0F20917686MEN

## Abstracts

### Report Summary

Hematologic Malignancies-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Hematologic Malignancies industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Hematologic Malignancies 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Hematologic Malignancies worldwide, with company and product introduction, position in the Hematologic Malignancies market

Market status and development trend of Hematologic Malignancies by types and applications

Cost and profit status of Hematologic Malignancies, and marketing status

Market growth drivers and challenges

The report segments the global Hematologic Malignancies market as:

Global Hematologic Malignancies Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Hematologic Malignancies Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Leukemia

Lymphoma

Multiple Myeloma

Others

Global Hematologic Malignancies Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Chemotherapy

Radiotherapy

Immunotherapy

Stem Cell Transplantation

Others

Global Hematologic Malignancies Market: Manufacturers Segment Analysis (Company and Product introduction, Hematologic Malignancies Sales Volume, Revenue, Price and Gross Margin):

Pfizer, Inc.

F. Hoffmann-LA Roche Ltd

Sanofi-Aventis

Bristol-Myers Squibb Company

AbbVie, Inc.

Novartis AG

GlaxoSmithKline PLC

Celgene Corporation

Johnson & Johnson Services, Inc.

Takeda Pharmaceutical Company limited

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF HEMATOLOGIC MALIGNANCIES**

- 1.1 Definition of Hematologic Malignancies in This Report
- 1.2 Commercial Types of Hematologic Malignancies
  - 1.2.1 Leukemia
  - 1.2.2 Lymphoma
  - 1.2.3 Multiple Myeloma
  - 1.2.4 Others
- 1.3 Downstream Application of Hematologic Malignancies
  - 1.3.1 Chemotherapy
  - 1.3.2 Radiotherapy
  - 1.3.3 Immunotherapy
  - 1.3.4 Stem Cell Transplantation
  - 1.3.5 Others
- 1.4 Development History of Hematologic Malignancies
- 1.5 Market Status and Trend of Hematologic Malignancies 2013-2023
  - 1.5.1 Global Hematologic Malignancies Market Status and Trend 2013-2023
  - 1.5.2 Regional Hematologic Malignancies Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Hematologic Malignancies 2013-2017
- 2.2 Sales Market of Hematologic Malignancies by Regions
  - 2.2.1 Sales Volume of Hematologic Malignancies by Regions
  - 2.2.2 Sales Value of Hematologic Malignancies by Regions
- 2.3 Production Market of Hematologic Malignancies by Regions
- 2.4 Global Market Forecast of Hematologic Malignancies 2018-2023
  - 2.4.1 Global Market Forecast of Hematologic Malignancies 2018-2023
  - 2.4.2 Market Forecast of Hematologic Malignancies by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Hematologic Malignancies by Types
- 3.2 Sales Value of Hematologic Malignancies by Types
- 3.3 Market Forecast of Hematologic Malignancies by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM**

## **INDUSTRY**

- 4.1 Global Sales Volume of Hematologic Malignancies by Downstream Industry
- 4.2 Global Market Forecast of Hematologic Malignancies by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Hematologic Malignancies Market Status by Countries
  - 5.1.1 North America Hematologic Malignancies Sales by Countries (2013-2017)
  - 5.1.2 North America Hematologic Malignancies Revenue by Countries (2013-2017)
  - 5.1.3 United States Hematologic Malignancies Market Status (2013-2017)
  - 5.1.4 Canada Hematologic Malignancies Market Status (2013-2017)
  - 5.1.5 Mexico Hematologic Malignancies Market Status (2013-2017)
- 5.2 North America Hematologic Malignancies Market Status by Manufacturers
- 5.3 North America Hematologic Malignancies Market Status by Type (2013-2017)
  - 5.3.1 North America Hematologic Malignancies Sales by Type (2013-2017)
  - 5.3.2 North America Hematologic Malignancies Revenue by Type (2013-2017)
- 5.4 North America Hematologic Malignancies Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Hematologic Malignancies Market Status by Countries
  - 6.1.1 Europe Hematologic Malignancies Sales by Countries (2013-2017)
  - 6.1.2 Europe Hematologic Malignancies Revenue by Countries (2013-2017)
  - 6.1.3 Germany Hematologic Malignancies Market Status (2013-2017)
  - 6.1.4 UK Hematologic Malignancies Market Status (2013-2017)
  - 6.1.5 France Hematologic Malignancies Market Status (2013-2017)
  - 6.1.6 Italy Hematologic Malignancies Market Status (2013-2017)
  - 6.1.7 Russia Hematologic Malignancies Market Status (2013-2017)
  - 6.1.8 Spain Hematologic Malignancies Market Status (2013-2017)
  - 6.1.9 Benelux Hematologic Malignancies Market Status (2013-2017)
- 6.2 Europe Hematologic Malignancies Market Status by Manufacturers
- 6.3 Europe Hematologic Malignancies Market Status by Type (2013-2017)
  - 6.3.1 Europe Hematologic Malignancies Sales by Type (2013-2017)
  - 6.3.2 Europe Hematologic Malignancies Revenue by Type (2013-2017)
- 6.4 Europe Hematologic Malignancies Market Status by Downstream Industry

(2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 7.1 Asia Pacific Hematologic Malignancies Market Status by Countries

7.1.1 Asia Pacific Hematologic Malignancies Sales by Countries (2013-2017)

7.1.2 Asia Pacific Hematologic Malignancies Revenue by Countries (2013-2017)

7.1.3 China Hematologic Malignancies Market Status (2013-2017)

7.1.4 Japan Hematologic Malignancies Market Status (2013-2017)

7.1.5 India Hematologic Malignancies Market Status (2013-2017)

7.1.6 Southeast Asia Hematologic Malignancies Market Status (2013-2017)

7.1.7 Australia Hematologic Malignancies Market Status (2013-2017)

### 7.2 Asia Pacific Hematologic Malignancies Market Status by Manufacturers

### 7.3 Asia Pacific Hematologic Malignancies Market Status by Type (2013-2017)

7.3.1 Asia Pacific Hematologic Malignancies Sales by Type (2013-2017)

7.3.2 Asia Pacific Hematologic Malignancies Revenue by Type (2013-2017)

### 7.4 Asia Pacific Hematologic Malignancies Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 8.1 Latin America Hematologic Malignancies Market Status by Countries

8.1.1 Latin America Hematologic Malignancies Sales by Countries (2013-2017)

8.1.2 Latin America Hematologic Malignancies Revenue by Countries (2013-2017)

8.1.3 Brazil Hematologic Malignancies Market Status (2013-2017)

8.1.4 Argentina Hematologic Malignancies Market Status (2013-2017)

8.1.5 Colombia Hematologic Malignancies Market Status (2013-2017)

### 8.2 Latin America Hematologic Malignancies Market Status by Manufacturers

### 8.3 Latin America Hematologic Malignancies Market Status by Type (2013-2017)

8.3.1 Latin America Hematologic Malignancies Sales by Type (2013-2017)

8.3.2 Latin America Hematologic Malignancies Revenue by Type (2013-2017)

### 8.4 Latin America Hematologic Malignancies Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 9.1 Middle East and Africa Hematologic Malignancies Market Status by Countries
  - 9.1.1 Middle East and Africa Hematologic Malignancies Sales by Countries (2013-2017)
  - 9.1.2 Middle East and Africa Hematologic Malignancies Revenue by Countries (2013-2017)
  - 9.1.3 Middle East Hematologic Malignancies Market Status (2013-2017)
  - 9.1.4 Africa Hematologic Malignancies Market Status (2013-2017)
- 9.2 Middle East and Africa Hematologic Malignancies Market Status by Manufacturers
- 9.3 Middle East and Africa Hematologic Malignancies Market Status by Type (2013-2017)
  - 9.3.1 Middle East and Africa Hematologic Malignancies Sales by Type (2013-2017)
  - 9.3.2 Middle East and Africa Hematologic Malignancies Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Hematologic Malignancies Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Hematologic Malignancies Downstream Industry Situation and Trend Overview

## **CHAPTER 11 HEMATOLOGIC MALIGNANCIES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

- 11.1 Production Volume of Hematologic Malignancies by Major Manufacturers
- 11.2 Production Value of Hematologic Malignancies by Major Manufacturers
- 11.3 Basic Information of Hematologic Malignancies by Major Manufacturers
  - 11.3.1 Headquarters Location and Established Time of Hematologic Malignancies Major Manufacturer
  - 11.3.2 Employees and Revenue Level of Hematologic Malignancies Major Manufacturer
- 11.4 Market Competition News and Trend
  - 11.4.1 Merger, Consolidation or Acquisition News
  - 11.4.2 Investment or Disinvestment News
  - 11.4.3 New Product Development and Launch

## **CHAPTER 12 HEMATOLOGIC MALIGNANCIES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

## 12.1 Pfizer, Inc.

12.1.1 Company profile

12.1.2 Representative Hematologic Malignancies Product

12.1.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Pfizer, Inc.

## 12.2 F. Hoffmann-LA Roche Ltd

12.2.1 Company profile

12.2.2 Representative Hematologic Malignancies Product

12.2.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of F. Hoffmann-LA Roche Ltd

## 12.3 Sanofi-Aventis

12.3.1 Company profile

12.3.2 Representative Hematologic Malignancies Product

12.3.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Sanofi-Aventis

## 12.4 Bristol-Myers Squibb Company

12.4.1 Company profile

12.4.2 Representative Hematologic Malignancies Product

12.4.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

## 12.5 AbbVie, Inc.

12.5.1 Company profile

12.5.2 Representative Hematologic Malignancies Product

12.5.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of AbbVie, Inc.

## 12.6 Novartis AG

12.6.1 Company profile

12.6.2 Representative Hematologic Malignancies Product

12.6.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Novartis AG

## 12.7 GlaxoSmithKline PLC

12.7.1 Company profile

12.7.2 Representative Hematologic Malignancies Product

12.7.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of GlaxoSmithKline PLC

## 12.8 Celgene Corporation

12.8.1 Company profile

12.8.2 Representative Hematologic Malignancies Product

12.8.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Celgene



Corporation

12.9 Johnson & Johnson Services, Inc.

12.9.1 Company profile

12.9.2 Representative Hematologic Malignancies Product

12.9.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Johnson & Johnson Services, Inc.

12.10 Takeda Pharmaceutical Company limited

12.10.1 Company profile

12.10.2 Representative Hematologic Malignancies Product

12.10.3 Hematologic Malignancies Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company limited

## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

13.1 Industry Chain of Hematologic Malignancies

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF HEMATOLOGIC MALIGNANCIES**

14.1 Cost Structure Analysis of Hematologic Malignancies

14.2 Raw Materials Cost Analysis of Hematologic Malignancies

14.3 Labor Cost Analysis of Hematologic Malignancies

14.4 Manufacturing Expenses Analysis of Hematologic Malignancies

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference



## I would like to order

Product name: Hematologic Malignancies-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/H0F20917686MEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0F20917686MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970